Mark Shilkrut

2.0k citations

45 papers · 1.3k indexed · h-index 16

Impact in

Oncology top 10%
- CAR-T cell therapy research
Cell Biology top 10%
- Hemoglobin structure and function

Papers in

Oncology 23
- CAR-T cell therapy research 13
Biotechnology 6
- Cancer Research and Treatments 6

Co-authors: Ofer Binah Naama Zeevi‐Levin Asaf Danon Joseph Itskovitz‐Eldor Katya Dolnikov Howard L. Kaufman Robert H.I. Andtbacka Frances A. Collichio
Journals: Annals of Oncology (4 papers)Journal of Clinical Oncology (4 papers)Journal for ImmunoTherapy of Cancer (3 papers)Cardiovascular Research (2 papers)Circulation Research (2 papers)
Partner nations: United States Israel Australia

In The Last Decade

Mark Shilkrut

45 papers receiving 1.3k citations

Peers

Countries citing papers authored by Mark Shilkrut

Since Specialization

Citations

This map shows the geographic impact of Mark Shilkrut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Shilkrut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Shilkrut more than expected).

Fields of papers citing papers by Mark Shilkrut

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Shilkrut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Shilkrut. The network helps show where Mark Shilkrut may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark Shilkrut, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Shilkrut Line = papers co-authored together Mark Shilkrut links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data BMC Cancer ·Qiufei Ma, Mark Shilkrut, Zhongyun Zhao, Minming Li, Nicolas Batty, Beth Barber	2018	16
2	Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma Annals of Oncology ·Georgina V. Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion‐Sileni, James Larkin, Caroline Robert, Dirk Schadendorf, Kohinoor Dasgupta, Mark Shilkrut, James E. Garrett, Jan C. Brase, Richard Kefford, John M. Kirkwood, Reinhard Dummer	2018	13
3	EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC) Annals of Oncology ·M. Martín Jiménez, Thomas Bachelot, Carlos H. Barrios, Kimberly Blackwell, Stephen Chia, Michelino De Laurentiis, Sara A. Hurvitz, Wolfgang Janni, Bella Kaufman, Sherene Loi, Peter Schmid, DJ Slamon, Katharine Hazell, S. Mondal, Mark Shilkrut, Caroline Germa, Gabriel N. Hortobágyi	2017	4
4	Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials Journal for ImmunoTherapy of Cancer ·Howard L. Kaufman, Robert H.I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, Merrick I. Ross	2017	34
5	Prevalence Of Autoimmune Comorbidities In Patients With Metastatic Melanoma In The United States Value in Health ·Qi Ma, Mark Shilkrut, Kim Young-Wun, BL Barber, Zhongyun Zhao	2016	1
6	Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis Advances in Therapy ·Qiufei Ma, Zhongyun Zhao, Beth Barber, Mark Shilkrut	2016	7
7	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial Annals of Surgical Oncology ·Robert H.I. Andtbacka, Merrick Ross, Igor Puzanov, Mohammed Milhem, Frances A. Collichio, Keith A. Delman, Thomas Amatruda, Jonathan S. Zager, Lee D. Cranmer, Eddy C. Hsueh, Lisa Chen, Mark Shilkrut, Howard L. Kaufman	2016	240
8	Development and Validation of a Novel Platform-Independent Metastasis Signature in Human Breast Cancer PLoS ONE ·Shuang G. Zhao, Mark Shilkrut, Corey Speers, Meilan Liu, Kari Wilder-Romans, Theodore S. Lawrence, Lori J. Pierce, Felix Y. Feng	2015	10
9	Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy American Journal of Clinical Oncology ·Mark Shilkrut, Patrick W. McLaughlin, Gregory S. Merrick, Jeffrey M. Vainshtein, Daniel A. Hamstra	2014	9
10	The addition of low‐dose‐rate brachytherapy and androgen‐deprivation therapy decreases biochemical failure and prostate cancer death compared with dose‐escalated external‐beam radiation therapy for high‐risk prostate cancer Cancer ·Mark Shilkrut, Gregory S. Merrick, Patrick W. McLaughlin, Matthew H. Stenmark, Eyad Abu‐Isa, Sean Vance, Howard M. Sandler, Felix Y. Feng, Daniel A. Hamstra	2012	34
11	Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes Journal of Clinical Investigation ·Michael A. Augello, Craig J. Burd, Ruth Birbe, Christopher McNair, Adam Ertel, Michael S. Magee, Daniel E. Frigo, Kari Wilder-Romans, Mark Shilkrut, Sumin Han, Danielle L. Jernigan, Jeffry L. Dean, Alessandro Fatatis, Donald P. McDonnell, Tapio Visakorpi, Felix Y. Feng, Karen E. Knudsen	2012	35
12	Secondary malignancies in survivors of breast cancer: How to overcome the risk Critical Reviews in Oncology/Hematology ·Mark Shilkrut, Yazid Belkacémi, Abraham Kuten	2011	14
13	Low-Dose Iodine-131 Metaiodobenzylguanidine Therapy for Patients With Malignant Pheochromocytoma and Paraganglioma American Journal of Clinical Oncology ·Mark Shilkrut, R. Bar-Deroma, Gil Bar‐Sela, Katarina Benković, Abraham Kuten	2010	30
14	Functional and developmental properties of human embryonic stem cells–derived cardiomyocytes Journal of Electrocardiology ·Ofer Binah, Katya Dolnikov, Mexas Mirian Picinini, Mark Shilkrut, Naama Zeevi‐Levin, Michal Amit, Asaf Danon, Joseph Itskovitz‐Eldor	2007	62
15	Hydrogen peroxide predisposes neonatal rat ventricular myocytes to Fas-mediated apoptosis Biochemical and Biophysical Research Communications ·Kozłowski Tomasz, Mark Shilkrut, Sarit Larisch, Ofer Binah	2005	15
16	The 1,4,5-inositol trisphosphate pathway is a key component in Fas-mediated hypertrophy in neonatal rat ventricular myocytes Cardiovascular Research ·Yaron D. Barac, Naama Zeevi‐Levin, Kozłowski Tomasz, Irina Reiter, Е.А. Климов, Mark Shilkrut, Herbert Schmid, Zaid Abassi, Ofer Binah	2005	35
17	The Fas Receptor—1,4,5‐IP₃ Cascade: A Potential Target for Treating Heart Failure and Arrhythmias Annals of the New York Academy of Sciences ·Ofer Binah, Mark Shilkrut, Kozłowski Tomasz, Sarit Larisch	2004	14
18	Tyrosine kinases inhibitors block Fas-mediated deleterious effects in normoxic and hypoxic ventricular myocytes Journal of Molecular and Cellular Cardiology ·Mark Shilkrut	2003	14
19	Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the Fas (CD95/Apo-1) receptor: Fas activation and apoptosis in hypoxic myocytes Cardiovascular Research ·C H. Lee, Mark Shilkrut, Rachel Lotan, Gideon Berke, Sarit Larisch, Ofer Binah	2002	52
20	Cardiac Dysfunction in Murine Autoimmune Myocarditis Journal of Autoimmunity ·Vũ Quốc Đạt, Mark Shilkrut, Israel Rubinstein, Gideon Berke, Ofer Binah	1999	11

About Mark Shilkrut

Mark Shilkrut is a scholar working on Oncology, Biotechnology, Genetics, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine, having authored 45 papers that have together received 1.3k indexed citations. Recurring topics across this work include CAR-T cell therapy research (13 papers), Virus-based gene therapy research (9 papers), Cardiac electrophysiology and arrhythmias (8 papers), Cancer Research and Treatments (6 papers), Melanoma and MAPK Pathways (5 papers), Prostate Cancer Diagnosis and Treatment (5 papers), Prostate Cancer Treatment and Research (5 papers) and Cell death mechanisms and regulation (4 papers). The work is most often cited by research in Oncology (378 citations), Cell Biology (176 citations), Genetics (267 citations), Molecular Biology (648 citations) and Immunology (189 citations). Mark Shilkrut has collaborated with scholars based in United States, Israel and Australia. Frequent co-authors include Ofer Binah, Naama Zeevi‐Levin, Asaf Danon, Joseph Itskovitz‐Eldor, Katya Dolnikov, Howard L. Kaufman, Robert H.I. Andtbacka, Frances A. Collichio, Thomas Amatruda and Michal Amit. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Cardiovascular Research and Circulation Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact